TAIZHOU, China, Aug. 19, 2019 /PR Newswire/ -- China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), today announced that its Annual Report on From 20-F for the fiscal year ended March 31, 2019 has been filed with the U.S. Securities and Exchange Commission (the "SEC") on August 15, 2019. An electronic copy of the annual report on Form 20-F can be accessed on China SXT's website at http://www.sxtchina.com and on the SEC's website at www.sec.gov. Shareholders may receive a hard copy of China SXT's audited financial statement for the fiscal year ended March 31, 2019 free of charge upon request.
TAIZHOU, China, Aug. 12, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), announced today that it has been issued a new Certificate of GMP (Good Manufacturing Practice) for Pharmaceutical Products (the "Certificate") by the Food and Drug Administration of Jiangsu Province, China ("FDA"). The FDA staff conducted its on-site examination in accordance with government regulations.
China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC) announced today that on December 27, 2019 the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that the minimum bid price per share for its common shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2).
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that a fund granted to the Company for the key techniques incorporated into advanced Directly-Oral TCMPs derived from agriculture has been approved on February 19, 2020, by the Hailing District Science and Technology Bureau of Taizhou city.
China SXT Pharmaceuticals (NASDAQ:SXTC) shares have had a really impressive month, gaining 45%, after some slippage...
TAIZHOU, China, Sept. 11, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, ...
To the annoyance of some shareholders, China SXT Pharmaceuticals (NASDAQ:SXTC) shares are down a considerable 31% in...
Today we are going to look at China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) to see whether it might be an attractive...
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that its DNA Exam Laboratory completely built in October of 2019 recently has been approved by Jiangsu province Drug Administration (JSDA). The Laboratory has been granted to perform research and development (R&D;) and quality control of TCM raw materials and TCMP products applying DNA testing technology.
TAIZHOU, China, July 3, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), today announced that it has begun the production of TCM Homologous Supplements ("TCMHS"), a classification of health-supporting food used traditionally in China as TCM but which are also consumed as food. The Company recently reconstructed and assembled an 850-square-meter facility and received a "Food Manufacturing Certificate" issued by the local Food and Drug Administration, which granted the Company permission to produce TCMHS.